

Datasheet: MCA1085F

BATCH NUMBER 164413

Description:	MOUSE ANTI HORSE MHC CLASS II MONOMORPHIC:FITC
Specificity:	MHC CLASS II MONOMORPHIC
Format:	FITC
Product Type:	Monoclonal Antibody
Clone:	CVS20
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species

Horse

Species Cross Reactivity

Reacts with: Human, Bovine, Dog

N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

Product Form

Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid

Max Ex/Em

Fluorophore	Excitation Max (nm)	Emission Max (nm)
FITC	490	525

Preparation

Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

Buffer Solution

Phosphate buffered saline

Preservative 0.09% sodium azide (NaN₃)
Stabilisers 1% bovine serum albumin

Approx. Protein Concentrations IgG concentration 0.1 mg/ml

Immunogen 3132 cells.

Fusion Partners Spleen cells from immunised BALB/c mice were fused with cells of the X.63-Ag8.653 mouse myeloma cell line

Specificity **Mouse anti Horse MHC Class II Monomorphic antibody, clone CVS20** recognizes monomorphic equine MHC Class II and was classified at the International Equine Leucocyte Antigen Workshop. Clone CVS20 reacts with all equine B cells and 95% of equine T cells.

The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In horses, this is referred to as the equine leukocyte antigen (ELA) region.

Flow Cytometry Use 10µl of the suggested working dilution to label 10⁶ cells in 100µl

- References**
1. Lunn, D.P. *et al.* (1998) Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995. [Vet Immunol Immunopathol. 62 \(2\): 101-43.](#)
 2. Weiss, D.J. *et al.* (2001) Regulation of expression of major histocompatibility antigens by bovine macrophages infected with *Mycobacterium avium* subsp. *paratuberculosis* or *Mycobacterium avium* subsp. *avium*. [Infect Immun. 69 \(2\): 1002-8.](#)
 3. Out, T.A. *et al.* (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs. [Immunology. 105 \(4\): 499-508.](#)
 4. Catchpole, B. *et al.* (2002) Generation of blood-derived dendritic cells in dogs with oral malignant melanoma. [J Comp Pathol. 126: 238-41.](#)
 5. Weiss, D.J. *et al.* (2006) Mucosal immune response in cattle with subclinical Johne's disease. [Vet Pathol. 43: 127-35.](#)
 6. Sassa, Y. *et al.* (2010) Bovine macrophage degradation of scrapie and BSE PrPSc [Vet Immunol Immunopathol. 133: 33-9.](#)
 7. Carrade, D.D. *et al.* (2011) Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. [Cytotherapy. 13: 419-30.](#)
 8. Weiss, D.J. (2001) Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies. [Vet Pathol. 38: 512-8.](#)
 9. Carrade, D.D. *et al.* (2012) Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells(). [Cell Med. 4 \(1\): 1-11.](#)
 10. Hussein, H. *et al.* (2016) Cathepsin K inhibition renders equine bone marrow nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation *in vitro*. [Comp Immunol Microbiol Infect Dis. 45: 40-7.](#)
 11. Hussein, H. *et al.* (2016) Cathepsin K inhibition renders equine bone marrow nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation *in vitro*. [Comp Immunol Microbiol Infect Dis. 45: 40-7.](#)

12. de Moraes, C.N. *et al.* (2016) Bovine endometrial cells: a source of mesenchymal stem/progenitor cells. [Cell Biol Int. 40 \(12\): 1332-1339.](#)
13. Maumus, M. *et al.* (2016) Utility of a Mouse Model of Osteoarthritis to Demonstrate Cartilage Protection by IFN γ -Primed Equine Mesenchymal Stem Cells. [Front Immunol. 7: 392.](#)
14. Ziegler, A. *et al.* (2016) Identification and characterization of equine blood plasmacytoid dendritic cells. [Dev Comp Immunol. 65: 352-7.](#)
15. Maia, L. *et al.* (2017) A proteomic study of mesenchymal stem cells from equine umbilical cord. [Theriogenology. 100: 8-15.](#)
16. Maia, L. *et al.* (2017) Conditioned medium: a new alternative for cryopreservation of equine umbilical cord mesenchymal stem cells. [Cell Biol Int. 41 \(3\): 239-48.](#)
17. Abdelhamid, L. *et al.* (2017) Retinoic acid-mediated anti-inflammatory responses in equine immune cells stimulated by LPS and allogeneic mesenchymal stem cells. [Res Vet Sci. 114: 225-32.](#)
18. Barberini, D.J. *et al.* (2018) Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses. [Stem Cell Res Ther. 9 \(1\): 96.](#)
19. Dos Santos, V.H. *et al.* (2019) Evaluation of alginate hydrogel encapsulated mesenchymal stem cell migration in horses. [Res Vet Sci. 124: 38-45.](#)
20. Witonsky, S. *et al.* (2019) Can levamisole upregulate the equine cell-mediated macrophage (M1) dendritic cell (DC1) T-helper 1 (CD4 Th1) T-cytotoxic (CD8) immune response *in vitro*? [J Vet Intern Med. 33 \(2\): 889-96.](#)
21. Lopez, B.S. *et al.* (2019) The effect of age on foal monocyte-derived dendritic cell (MoDC) maturation and function after exposure to killed bacteria. [Vet Immunol Immunopathol. 210: 38-45.](#)
22. Lucassen, A. *et al.* (2021) A *Saccharomyces cerevisiae* Fermentation Product (Olimond BB) Alters the Early Response after Influenza Vaccination in Racehorses. [Animals \(Basel\). 18;11\(9\):2726.](#)
23. Korbonits, L. *et al.* (2022) *Mycobacterium avium* subsp. *paratuberculosis* Infected Cows Reveal Divergent Immune Response in Bovine Peripheral Blood Derived Lymphocyte Proteome. [Metabolites. 12 \(10\): 924.](#)
24. Lopez, B.S. *et al.* (2020) Phenotypic characterization of equine monocyte-derived dendritic cells generated ex vivo utilizing commercially available serum-free medium. [Vet Immunol Immunopathol. 222: 110036.](#)
25. Lopez, B.S. *et al.* (2020) The effect of foal or adult horse plasma on equine monocyte-derived dendritic cell phenotype and function. [Vet Immunol Immunopathol. 228: 110099.](#)
26. Lopez, B.S. *et al.* (2024) The effect of cortisol on equine monocyte-derived dendritic cell phenotype and cytokine production [Vet Med Sci. 10 \(2\): e1333 \[Epub ahead of print\].](#)
27. Cabezas, J. *et al.* (2020) *In vitro* preconditioning of equine adipose mesenchymal stem cells with prostaglandin E(2), substance P and their combination changes the cellular protein secretomics and improves their immunomodulatory competence without compromising stemness. [Vet Immunol Immunopathol. 228: 110100.](#)
28. Terpeluk, R.E. *et al.* (2024) Supplementation of Foals with a *Saccharomyces cerevisiae* Fermentation Product Alters the Early Response to Vaccination [Animals. 14 \(6\): 960.](#)

Further Reading

1. Burk, J. *et al.* (2013) Equine cellular therapy-from stall to bench to bedside? [Cytometry A. 83: 103-13](#)
-

Storage This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Guarantee 12 months from date of despatch

Health And Safety Information Material Safety Datasheet documentation #10041 available at: <https://www.bio-rad-antibodies.com/SDS/MCA1085F>
10041

Regulatory For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M408075:221010'

Printed on 25 Mar 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)